Gennady Geskin, MD
Cardiovascular Disease · Jefferson Hills, PANPI 1053319434
Payments from drug & device makers
What this record shows
This record is dominated by other: $159,824 of the $244,400 with a category attached, or 65.4%. 57 manufacturers reported payments, led by Angiodynamics, Inc. at 56.3% of the total. Reporting peaked in 2024 at $79,422 and has fallen 84.3% since, to $12,479 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 873 payments — averaging $279.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$138K
- Philips North America LLC$33K
- Skye Orthobiologics LLC$29K
- Abbott$13K
- Guerbet LLC$7K
- Boston Scientific$4K
- plus $21K from 51 others
Across 26 payments — averaging $2903.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Veryan Medical Incorporated$75K
What the payments were for
- Consulting fees$15,2506%
- Speaking & faculty fees$30,40012%
- Travel & lodging$8,3633%
- Food & beverage$24,84410%
- Education$5,7202%
- Other$159,82465%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$136,272
- IGT D Peripheral$22,664
- Spectranetics Undiv$9,800
- Omnilink Elite vascular stent system$8,800
- Lipiodol$6,641
- Emboshield NAV6 system$2,400
- Peripheral Orbital Atherectomy System$1,455
- Coronary Orbital Atherectomy System$635
- BioMimics3D Stent System$556
- Alto Abdominal Stent Graft System$399
- BioMimics$397
- Absolute Pro vascular stent system$379
- EMBLEM$351
- GENERAL VASCULAR INTERVENTION$284
- Supera peripheral stent system$279
- EMBLEM MRI S-ICD$271
- FLOWTRIEVER CATHETER, S$266
- CT THROMBECTOMY SYSTEM KIT$266
- CoreValve Evolut$256
- COREVALVE EVOLUT R$245
How this compares
$244,400 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 310 | $326,865 |
| XareltoRivaroxaban | 128 | $124,374 |
| Repatha SureclickEvolocumab | 93 | $80,910 |
| BrilintaTicagrelor | 64 | $57,173 |
| EntrestoSacubitril/Valsartan | 57 | $53,602 |
| Nebivolol Hcl | 83 | $4,333 |
| ClopidogrelClopidogrel Bisulfate | 407 | $4,280 |
| Rosuvastatin Calcium | 209 | $4,174 |
| Atorvastatin Calcium | 153 | $2,088 |
| Enoxaparin Sodium | 18 | $1,646 |
| Niacin ErNiacin | 16 | $1,470 |
| Metoprolol Succinate | 60 | $1,082 |
| Bumetanide | 19 | $1,052 |
| Carvedilol | 122 | $864 |
| Amlodipine Besylate | 81 | $576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $731 | $326,865310 claims |
| Johnson & JohnsonXarelto | $1,718 | $124,374128 claims |
| AstraZenecaBrilinta | $775 | $57,17364 claims |
| NovartisEntresto | $469 | $53,60257 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Jefferson Hills
- Amish MehtaJefferson Hills$132K
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.